American Society of Hirudotherapy

Recombinant hirudin: genetic engineering and structure analysis

Research article published in Seminars in thrombosis and hemostasis (1991)

Last Updated: March 18, 2026Reviewed by: ASH Editorial Board
Drug DevelopmentMärki W et al. · Seminars in thrombosis and hemostasis, 1991

Summary

Recombinant hirudin: genetic engineering and structure analysis.

Why This Matters for Hirudotherapy

Relevant to the development and clinical application of leech-derived pharmaceutical compounds.

Citation

Recombinant hirudin: genetic engineering and structure analysis.

Märki W et al. · Seminars in thrombosis and hemostasis, 1991

DOI

Added to ASH library: March 18, 2026 · Site last updated: March 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.